US biotech companies Biogen and Neomorph have announced a research collaboration to discover and develop molecular glue ...

Neomorph will receive an upfront payment and may earn contingent milestone payments as the collaboration advances.

Biogen is the latest big biotech to make a play in protein degradation. The Massachusetts-based company has announced a deal to use Neomorph’s molecular glue degrader discovery platform to go after ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Biogen (BIIB) announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, ...

Two days after Monte Rosa Therapeutics Inc. signed a molecular glue degrader deal with Novartis AG, two other companies, Biogen Inc. and Neomorph Inc., are moving forward in the same space in a ...

(RTTNews) - Biogen Inc. (BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer's, rare neurological ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

Needham analyst Ami Fadia has maintained their bullish stance on BIIB stock, giving a Buy rating yesterday. Ami Fadia has given her Buy rating ...

Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the treatment of Alzheimer’s disease and other neurological and ...